Business / Finance

RSS

Rite Aid announces acquisition of Houston-based RediClinic

Rite Aid Corporation announced today it has acquired Houston-based RediClinic, one of the nation's leading operators of retail clinics. RediClinic currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Through the acquisition, RediClinic will operate as a wholly owned subsidiary of Rite Aid. Details of the transaction were not disclosed.

10 Apr 2014

Neurovive stock now trading in the US between $4.00 and $4.21

NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on March 20, 2014.

10 Apr 2014

Gerresheimer’s revenues increase EUR 297.5M to 0.3% in first quarter 2014

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, began financial year 2014 with a solid start."I am satisfied with our performance in the first quarter of 2014.

10 Apr 2014

Covaris' European subsidiary to commence operations on May 1, 2014

Covaris, Inc., an innovator in the life science tools and the clinical diagnostic market spaces, announced today that its European subsidiary, Covaris Ltd, which is located in the United Kingdom, will commence operations on May 1, 2014.

10 Apr 2014

Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.

9 Apr 2014

Millennium Medical Devices inks another network selling agreement

Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.

9 Apr 2014

bioTheranostics, Prime Health Services sign contract to expand genomic tests

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, has signed a contract with Prime Health Services, Inc., a national preferred provider organization network, to cover the company's genomic tests for breast cancer patients and patients with metastatic disease.

9 Apr 2014

Bay Area Medical Center renews contract for Zix Email Encryption in a three-year agreement

Zix Corporation (ZixCorp), a leader in email data protection, announced that Bay Area Medical Center has renewed its contract for ZixTM Email Encryption in a three-year agreement.

9 Apr 2014

LabStyle Innovations, FatSecret partner for Dario Diabetes Management Solution

LabStyle Innovations Corp., developer of the Dario Diabetes Management Solution, today announced a partnership with the world's leading global nutrition data application, FatSecret.

9 Apr 2014

Spero Therapeutics enters into antibiotics partnership with Roche

Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche.

9 Apr 2014

Medison Pharma inks agreement with Brainsway for exclusive marketing of Deep TMS system in Israel

Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel.

9 Apr 2014

Quantum Imaging secures £1.6 million investment to develop medical imaging device

Quantum Imaging Ltd, a University of Leeds spin out, has secured a £1.6 million investment to develop its medical imaging technology.

8 Apr 2014

Menicon donates 3 million yen to revitalization of soccer pitches in Tohoku

Menicon Co., Ltd., Japan's leading contact lens manufacturer, recently donated 3 million yen plus staff volunteer time to the revitalization of three soccer pitches in the Tohoku region, as part of an ongoing effort to assist communities stricken by the earthquake, tsunami and nuclear disasters of March 11, 2011.

8 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9.

8 Apr 2014

Meda reaches agreement with Valeant to terminate joint ventures

Meda has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates have been established.

7 Apr 2014

Exact Sciences announces pricing of underwritten public offering of common stock

Exact Sciences Corp. today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public.

4 Apr 2014

Bjond raises $3.25M in Series A financing to accelerate its flagship software

Today Bjond, Inc. announced that it closed $3.25 million in Series A financing. Draper Triangle Ventures led the round, joined by co-investors TriStar Technology Ventures and Hopen Life Science Ventures.

4 Apr 2014

Bio-Techne makes $10M equity investment in CyVek

Techne Corporation, d/b/a Bio-Techne, announced today that it has made a $10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future milestones are met.

4 Apr 2014

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.

4 Apr 2014